New Delhi: Manufacturer of COVID-19 vaccine, Covaxin, on Sunday claimed to have produced neutralising titres (concentration) against all key emerging variants tested, including the B.1.617 and B.1.1.7, first identified in India and the United Kingdom.
A modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to the vaccine variant (D614G), said Bharat Biotech.
— suchitra ella (@SuchitraElla) May 16, 2021
Bharat Biotech joint managing director Suchitra Ella cited a study published in peer-reviewed medical journal Clinical Infectious Diseases.
It, however, added that despite this reduction, neutralizing titre levels with B.!.617 remain above levels expected to be protective.
“No difference in neutralization between B.1.1.7 (first found in the UK) and vaccine strain (D614G) was observed,” Bharat Biotech added.
These findings are from a study conducted in collaboration with the National Institute of Virology – India Council of Medical Research.
It is to be mentioned that, Covaxin is one of the three Covid-19 vaccines that are currently available in the country.
As per the Union Health Ministry, a total of 18,22,20,164 doses of Covid-19 vaccines have been administered across the country so far.